荷兰多发性骨髓瘤35年发病率与生存趋势
Multiple myeloma in the Netherlands: 35-year trends in incidence and survival
基于荷兰癌症登记处的回顾性研究显示,1989至2022年间33960例多发性骨髓瘤患者的发病率保持稳定,约为每10万人每年5.3例。接受系统治疗患者的中位总生存期从1989-1999年的26个月显著延长至2013-2017年的59个月。
Introduction
Multiple myeloma (MM) has an incidence of 4.5–6.0 per 100,000 individuals and a median age at diagnosis of 70 years in Europe [1]. The treatment of MM has advanced rapidly over the past decades, translating into substantial overall survival (OS) improvements [1, 2].
Historically, treatment was solely chemotherapy based. The 1990s marked the introduction of high dose melphalan followed by autologous stem cell transplantation (HDT/ASCT) [3]. In the 2000s, the immunomodulatory drugs (IMiD) thalidomide and lenalidomide, and the proteasome inhibitor (PI) bortezomib became available [4, 5]. During the early 2010s, pomalidomide, carfilzomib, and ixazomib were introduced [6]. From 2013 onwards, HDT/ASCT eligibility was expanded up to 70 years [7]. More recently, anti-CD38 antibodies and cellular therapies were developed and are expected to further improve survival [8, 9].
Currently, quadruplet induction followed by HDT/ASCT is the preferred first-line treatment for patients < 70 years, with a pooled 7-year OS rate of 82.5% in trials [1, 10]. For patients > 70 years, anti-CD38 antibodies and lenalidomide with or without bortezomib achieve unprecedented PFS outcomes [1]. While trials show improved PFS or measurable residual disease (MRD) negativity, outcomes cannot routinely be translated to the real-world due to patient selection. Moreover, while the increase in OS necessitates the use of surrogate endpoints such as PFS and MRD, it remains important to show eventual benefit in OS.
We aim to provide insight into the impact of treatment advances on real-world survival outcomes, based on a nationwide cohort spanning 35 years.
Methods
This retrospective cohort study was conducted using the Netherlands Cancer Registry (NCR) [11]. This registry is maintained by the Netherlands Comprehensive Cancer Organization (IKNL) and covers over 95% of all malignancies nationwide since 1989. We included patients (aged ≥ 18 years) diagnosed with MM between 1989 and 2022, using the International Classification of Diseases for Oncology morphology code 9732. According to the Central Committee on Research involving Human Subjects (CCMO), this type of observational study does not require ethical approval in the Netherlands. The Privacy Review Board of the NCR approved the use of anonymized data.
Incidence rates were calculated for 33,960 patients using the European age-standardised rate (EASR) [12]. Survival analyses were limited to 24,142 patients treated with systemic therapy. The NCR records first-line treatment initiated within 12 months post-diagnosis. The untreated group included both patients with symptomatic MM in whom treatment was withheld and patients with smoldering MM without treatment indication. As the registry did not distinguish between these groups, patients who died within one year after diagnosis were retrospectively classified as symptomatic MM.
OS was defined as the time in months from diagnosis to death or censoring (February 1, 2024), whichever occurred first. Relative survival (RS) was defined as the ratio of the observed OS to the expected OS of the general population, matched for age and sex. Patients were divided into five eras, aligned with therapeutic advances: 1989–1999 (pre-transplant era), 2000–2007 (transplant era), 2008–2012 (IMiD/PI era), 2013–2017 (second-generation IMiD/PI era) and 2018–2022 (immunotherapy era). In these eras, non-HDT/ASCT-treatment generally consisted of melphalan-prednisolone, combined with thalidomide (2007–2011) or bortezomib (2012–2021), with daratumumab added from 2019. Since 2022, daratumumab-lenalidomide-dexamethasone became the standard. For HDT/ASCT-eligible patients, induction therapy was Adriamycin-dexamethasone with vincristine until thalidomide was introduced in 2005 and bortezomib in 2008, sequentially replacing vincristine. From 2012 onwards, induction was bortezomib-based, combined with cyclophosphamide (2012–2016) or thalidomide (2017–2022), with daratumumab added from 2022. Patients were further stratified in three age groups: 18–65, 66–70 and > 70, reflecting historical changes in HDT/ASCT eligibility, with patients aged > 70 not eligible for HDT/ASCT and patients aged 66–70 eligible from 2013 onwards.
Baseline characteristics were reported using counts, means, medians, and ranges as appropriate. The EASR was reported as number of patients per 100,000 persons per year. Trends in survival were assessed according to therapeutic era and age group. The median OS, alongside 95% confidence intervals (95% CI) was reported for the most recent therapeutic era with mature data. 2-year and 5-year RS rates were reported to compare age groups and therapeutic eras. OS and RS were visualized using the Kaplan-Meier method. Multivariable analysis on risk of mortality was performed taking sex and therapeutic era into account, stratifying for age group. The statistical analysis was performed in IBM SPSS (28) for Windows.
Results
Between 1989 and 2022, 33,960 patients with MM were identified. The EASR remained stable ( ~ 5 cases per 100,000 persons per year; 5.3 in 2018-2022) (Table 1 & Supplementary Fig. 1). Incidence increased with age and was highest in patients aged 80-84 with 40 cases per 100,000 persons per year. Twenty-nine percent of the total cohort was not treated in the first-year post-diagnosis. Of these, one-third was considered to have symptomatic MM in whom treatment was withheld, and two-thirds were considered to have smoldering MM without treatment indication (Supplementary Table 1). The proportion of untreated patients decreased significantly over time, mostly for patients > 70 years (Chi-square, p < 0.01). Among 24,142 patients treated with systemic therapy, the median age at diagnosis was 69 years (range 20–97 years); 39% of patients were aged 18–65, 17% 66–70 and 45% > 70. Fifty-seven percent of patients were male.
Median OS for the treated cohort more than doubled, from 26 months (95% CI, 25–27 months) in 1989–1999 to 59 months (95% CI, 56–61 months) in 2013–2017. Regarding the different age groups in the era 2013–2017, median OS was 111 months (95% CI, upper bound not reached) for patients aged 18–65, 64 months (95% CI, 58–69 months) for patients aged 66–70 and 37 months (95% CI, 35–39 months) for patients aged > 70 (Supplementary Fig. 2). Multivariable analysis confirmed a significantly reduced risk of mortality across successive therapeutic eras within each age group (p < 0.001) (Supplementary Table 2).
The 2-year and 5-year RS rates for all treated patients increased from 57% (95% CI, 55–57%) and 24% (95% CI, 23–26%), respectively, in 1989–1999 to 81% (95% CI, 79–82%) and 63% (95% CI, 60–65%) in 2018–2022. For patients aged 18–65, the largest percentage-point increase was observed in 2000–2007. Among patients aged 66–70, continuous improvement was seen across the most recent therapeutic eras. Consequently, the survival difference compared with patients aged 18–65 was reduced. Patients aged > 70 experienced the largest improvement in 2008–2012. In 2018–2022, 5-year RS rates were 74% (95% CI, 71–77%) for patients aged 18–65, 68% (95% CI, 63–73%) for patients aged 66–70, and 50% (95% CI, 47–54%) for patients aged > 70 (Fig. 1).
Figure showing the trends in relative survival over the years for patients diagnosed and treated between 1989 and 2022. A Relative survival for patients aged 18–65. The 2-year and 5-year RS improved from 65% and 32%, respectively, to 87% and 74% between 1989–1999 and 2018–2022. B Relative survival for patients aged 66–70. The 2-year and 5-year RS improved from 59% and 22%, respectively, to 84% and 68%. C Relative survival for patients aged > 70. The 2-year and 5-year RS improved from 48% and 18%, respectively, to 74% and 50%. Abbreviations: RS: Relative Survival.
Discussion
In this letter, we describe patterns in incidence and survival among patients with MM in the Netherlands over the past 35 years. The EASR was 5.3 per 100,000 persons per year between 2018 and 2022 and aligns with European estimates of 4.5–6.0 per 100,000 persons per year [1].
Survival has increased significantly since 1989. The 5-year RS rate increased by 42 percentage points for patients aged 18-65, 46 percentage points for patients aged 66-70, and 32 percentage points for patients older than 70 between 1989-1999 and 2018-2022. Across all age groups improved survival coincided with the introduction of new therapeutic options. For patients aged 18-65 and to a lesser extent patients aged 66-70, the introduction of HDT/ASCT was likely responsible for the biggest survival improvement. Advances in diagnostic accuracy and supportive care may have contributed to additional survival gains.
The 2018–2022 5-year RS rate of 63% for the treated population compares favorably to estimates observed in recent literature. Hemminki et al. reported a 5-year RS rate improvement from 24–25% to 53–54% between 1967–1971 and 2012–2016 in Sweden [13]. Similarly, Feletto et al. reported a 5-year RS rate improvement from 31% to 56% between 1985-1995 and 2008-2015 in Australia [14]. Here, we confirm these findings from Sweden and Australia while adding data until 2022. In addition, our analysis excludes patients in whom treatment was withheld and those with smoldering MM. Swan et al. reported a 5-year OS rate improvement in Europe for transplanted patients from 52% to 67% between 1995–1999 and 2010–2014 [15].
While significant survival improvements were seen for each age group, age-related differences persist and are likely related to comorbidity burden and diminished treatment tolerability (Supplementary Fig. 3). The use of therapeutic eras reflecting treatment advances – possibly benefitting younger patients earlier – may explain a delay in survival improvements for elderly patients. Since the effects of first-line anti-CD38 monoclonal antibodies were not captured in this timeframe, further survival gains may emerge. Still, a 24-percentage-point difference in RS exists between patients aged 18–65 and > 70, showing an unmet need for older patients.
A limitation of our study is the lack of detailed information on comorbidities and treatment, both in first and subsequent lines, limiting the ability to relate survival directly to applied treatments. Instead, we subdivided patients over eras, aligning with therapeutic advances. Strengths of our study include the large, nationwide cohort and long follow-up.
In conclusion, real-world survival in MM has improved substantially over the past 35 years in the Netherlands, reflecting therapeutic progress. However, outcomes for patients aged > 70 remain inferior, highlighting the need for more effective and tailored treatment strategies in older patients with MM.
References
Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22:680–700.
Brink M, Groen K, Sonneveld P, Minnema MC, Broijl A, Dinmohamed AG, et al. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer J. 2021;11:178.
Raje N, Anderson KC. Multiple myeloma. Curr Treat Options Oncol. 2000;1:73–82.
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.
Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–208.
Larocca A, Mina R, Gay F, Bringhen S, Boccadoro M. Emerging drugs and combinations to treat multiple myeloma. Oncotarget. 2017;8:60656–72.
Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi133–7.
Quezada-Ramírez SI, Del Carmen Tarín-Arzaga L, Gómez-De León A, Gómez-Almaguer D. Novel drug combinations for newly diagnosed multiple myeloma: how can we improve on current regimens? Expert Rev Hematol. 2025;18:359–72.
Engelhardt M, Kortüm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109:2420–35.
Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A. Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer J. 2025;15:37.
IKNL (Netherlands Comprehensive Cancer Organization). Netherlands Cancer Registry (NCR). Utrecht (The Netherlands): IKNL; 2024. Available from: https://iknl.nl/en/ncr. Accessed 2024.
Eurostat. Revision of the European Standard Population: Report of Eurostat’s task force. 2013 edition. Luxembourg: Publications Office of the European Union; 2013. ISBN: 978-92-79-31094-2. Available from: https://ec.europa.eu/eurostat/documents/3859598/5926869/KS-RA-13-028-EN.PDF
Hemminki K, Försti A, Hansson M. Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016. Sci Rep. 2021;11:17272.
Feletto E, Luo Q, Kelly A, Weber M, Goldsbury D, Barron K, et al. Multiple myeloma survival in New South Wales, Australia, by treatment era to 2020. Cancer Biol Med. 2024;21:703–11.
Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, et al. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. Br J Haematol. 2022;197:82–96.
Funding
KMK is supported by a MD/PhD scholarship from the UMCG. This study has been performed without further funding.
Author information
Authors and Affiliations
Department of Hematology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, Netherlands
Koen M. Klomberg, Wilfried W. H. Roeloffzen, Marcel Nijland, Gerwin A. Huls & Wouter J. Plattel
Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands
Mark-David Levin
Department of Internal Medicine & Hematology, Sint Antonius Hospital, Nieuwegein, Netherlands
Inger S. Nijhof
Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, Netherlands
Rimke Oostvogels & Monique C. Minnema
Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands
Elizabeth de Kort
Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
Ruth Wester & Annemiek Broijl
Department of Internal Medicine, Division of Hematology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, Netherlands
Catharina H. M. J. van Elssen
Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, Netherlands
Esther G. M. de Waal
Department of Internal Medicine, Isala Klinieken, Zwolle, Netherlands
Paul A. F. Geerts
Department of Internal Medicine, Admiraal De Ruyter Hospital, Goes, Netherlands
Yavuz M. Bilgin
Department of Hematology, Jeroen Bosch Hospital, Den Bosch, Netherlands
Djamila E. Issa & Laurens E. Franssen
Department of Hematology and Oncology, Amphia Hospital, Breda, Netherlands
Marjolein van de Klift
Department of Hematology, Medical Center Twente, Enschede, Netherlands
Cleo R. van Rooijen
Department of Internal Medicine, Haga Hospital, Den Haag, Netherlands
Paula F. Ypma
Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Niels W. C. J. van de Donk & Sonja Zweegman
Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, Netherlands
Mirian Brink
Authors
- Koen M. Klomberg
- Wilfried W. H. Roeloffzen
- Marcel Nijland
- Mark-David Levin
- Inger S. Nijhof
- Rimke Oostvogels
- Elizabeth de Kort
- Ruth Wester
- Catharina H. M. J. van Elssen
- Esther G. M. de Waal
- Paul A. F. Geerts
- Yavuz M. Bilgin
- Djamila E. Issa
- Marjolein van de Klift
- Gerwin A. Huls
- Laurens E. Franssen
- Cleo R. van Rooijen
- Monique C. Minnema
- Annemiek Broijl
- Paula F. Ypma
- Niels W. C. J. van de Donk
- Sonja Zweegman
- Mirian Brink
- Wouter J. Plattel
Contributions
KMK: Conceptualization, Methodology, Formal Analysis, Data Curation, Writing – Original Draft and Visualization; WWHR: Conceptualization, Supervision and Writing – Review & Editing; MN: Writing – Review & Editing; MDL: Writing – Review & Editing; ISN: Writing – Review & Editing; RO: Writing – Review & Editing; EdK: Writing – Review & Editing; RW: Writing – Review & Editing; CHMJvE: Writing – Review & Editing; EGMdW: Writing – Review & Editing; PAFG: Writing – Review & Editing; YMB: Writing – Review & Editing; DEI: Writing – Review & Editing; MvdK: Writing – Review & Editing; GAH: Writing – Review & Editing; LEF: Writing – Review & Editing; CRvR: Writing – Review & Editing; MCM: Writing – Review & Editing; AB: Writing – Review & Editing; PFY: Writing – Review & Editing; NWCJvdD: Writing – Review & Editing; SZ: Writing – Review & Editing; MB: Conceptualization, Methodology, Formal analysis, Data Curation and Writing – Review & Editing; WJP: Conceptualization, Supervision and Writing – Review & Editing.
Corresponding author
Correspondence to Koen M. Klomberg.
Ethics declarations
Competing interests
KMK: none; WWHR: Consultancy/honoraria: Janssen-Cilag, Celgene and Takeda; MN: Consultancy/honoraria: Roche Pharma, Celgene and BMS; MDL: Honoraria: Janssen Pharmaceuticals; ISN: Consultancy/honoraria: Janssen-Cilag, Kite and AbbVie. All paid to institution; RO: Consultancy/honoraria: Janssen Pharmaceuticals and Pfizer; EdK: Consultancy/honoraria: AbbVie, Pfizer and Gilead Sciences. All paid to institution; RW: Consultancy/honoraria: Janssen-Cilag, Amgen, Pfizer and Celgene; CHMJvE: Consultancy/honoraria: Janssen-Cilag, Amgen, Pfizer, Servier, Sanofi, all paid to the institution; EGMdW: none; PAFG: none; YMB: none; DEI: none; MvdK: none; GAH: none; LEF: Consultancy/honoraria: AbbVie, Amgen and Servier; CRvR: none; MCM: Research support from Janssen Pharmaceuticals and BeOne. Advisory board for Janssen Pharmaceuticals, AMGEN, Oncopeptides Celgene, BMS, Sanofi, Takeda and GSK. All paid to institution; AB: Consultancy/honoraria: Janssen-Cilag, Sanofi and BMS; PFY: consultancy/honoraria AOPHealth/Jansen-Cilag/Incyte/Amgen paid to the institution; NWCJvdD: Research support from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, Cellectis and BMS. Served in advisory boards for Janssen Pharmaceuticals, Amgen, Celgene, BMS, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Merck, Kite Pharma, Pfizer, AbbVie and Servier. All paid to Institution; SZ: Research support from Janssen Pharmaceuticals and Takeda. Served in Advisory boards for Janssen Pharmaceuticals, Amgen, Oncopeptides Celgene, BMS, Sanofi, Takeda and GSK. All paid to institution; MB: none; WJP: Consultancy/honoraria: Janssen -Cilag, Takeda and Pfizer.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Klomberg, K.M., Roeloffzen, W.W.H., Nijland, M. et al. Multiple myeloma in the Netherlands: 35-year trends in incidence and survival. Leukemia (2026). https://doi.org/10.1038/s41375-026-03156-1
Received: 13 May 2026
Revised: 09 September 2026
Accepted: 21 September 2026
Published: 22 October 2026
Version of record: 22 October 2026
DOI: https://doi.org/10.1038/s41375-026-03156-1
来源:Nature 健康护理主题 · nature.com